Warner King Huh

← Back to University of Alabama at Birmingham

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

   2015 · 1,429 citations

2. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors

   2020 · 1,406 citations

3. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

   2019 · 1,054 citations

4. 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors

   2013 · 922 citations

5. 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors

   2013 · 730 citations

6. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

   2018 · 643 citations

7. Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

   2010 · 566 citations

8. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

   2011 · 507 citations

9. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance

   2015 · 489 citations

10. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

    2017 · 465 citations

11. Therapeutic role of lymph node resection in endometrioid corpus cancer

    2006 · 406 citations

12. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

    2016 · 367 citations

13. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020

    2020 · 356 citations

14. Cervical Cancer, Version 2.2015

    2015 · 332 citations

15. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

    2012 · 316 citations

16. Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening

    2015 · 280 citations

17. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

    2023 · 205 citations

18. A multi-institutional review of outcomes of endometrial stromal sarcoma

    2007 · 204 citations

19. Uterine Neoplasms, Version 1.2014

    2014 · 182 citations

20. Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States

    2017 · 182 citations

21. Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease

    2014 · 176 citations

22. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

    2016 · 172 citations

23. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial

    2015 · 169 citations

24. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021

    2021 · 169 citations

25. Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma

    2009 · 166 citations

← Return to the university profile